Literature DB >> 3286880

The role of methotrexate in osteosarcoma.

J L Grem1, S A King, R E Wittes, B Leyland-Jones.   

Abstract

High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic issues concerning MTX therapy in osteosarcoma are discussed.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3286880     DOI： 10.1093/jnci/80.9.626

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


  11 in total

1.  Acetazolamide for alkalinisation of urine in patients receiving high-dose methotrexate.

Authors:  J Shamash; H Earl; R Souhami
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 2.  The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.

Authors:  Xin Xiao; Wei Wang; Zhen Wang
Journal:  Paediatr Drugs       Date:  2014-12       Impact factor: 3.022

Review 3.  Methotrexate for high-grade osteosarcoma in children and young adults.

Authors:  Elvira C van Dalen; Jorrit W van As; Beatriz de Camargo
Journal:  Cochrane Database Syst Rev       Date:  2011-05-11

Review 4.  Therapy for osteosarcoma: where do we go from here?

Authors:  Alexander J Chou; David S Geller; Richard Gorlick
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

5.  Clinical use of thymidine as a rescue agent from methotrexate toxicity.

Authors:  J L Grem; S A King; J M Sorensen; M C Christian
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

Review 6.  Chemotherapy for osteosarcoma.

Authors:  R L Souhami
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

7.  Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.

Authors:  M P Michelagnoli; I J Lewis; H R Gattamaneni; C C Bailey; L S Lashford
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

Review 8.  The efficacy and safety comparison of first-line chemotherapeutic agents (high-dose methotrexate, doxorubicin, cisplatin, and ifosfamide) for osteosarcoma: a network meta-analysis.

Authors:  Bin Zhang; Yan Zhang; Rongzhen Li; Jiazhen Li; Xinchang Lu; Yi Zhang
Journal:  J Orthop Surg Res       Date:  2020-02-13       Impact factor: 2.359

9.  Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.

Authors:  B Ory; G Moriceau; V Trichet; F Blanchard; M Berreur; F Rédini; M Rogers; D Heymann
Journal:  J Cell Mol Med       Date:  2008-06       Impact factor: 5.310

Review 10.  Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.

Authors:  Richa Rathore; Brian A Van Tine
Journal:  J Clin Med       Date:  2021-03-12       Impact factor: 4.964
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.